Background: To analyze the impact of metabolic syndrome on the safety and efficacy of flexible ureterorenoscopy (fURS) in managing kidney calculi.
Methods: We retrospectively analyzed the records of 151 patients who received fURS for the renal stones in our center between January 2014 and December 2016. The patients were divided into two groups based on whether they were diagnosed with metabolic syndrome. Information related to the patients, stones and surgeries were analyzed, and the stone-free rates (SFRs) and complications after fURS were reviewed.
Results: Group 1 consisted of patients with metabolic syndrome, and group 2 contained patients without metabolic syndrome. The mean stone size was 71.9±58.3 mm2 in group 1 and 64.9±43.7 mm2 in group 2 (P=0.399). The mean hospitalization and surgical durations were similar between both groups (P>0.05). The overall complication rates were 8.3% vs. 12.1% (P=0.514). The SFR at 3 months postoperative in group 1 was significantly lower than that in group 2 (80% vs. 92.3%, P<0.05).
Conclusions: Our study results revealed that patients with metabolic syndrome can be treated safely with fURS. however, metabolic syndrome has a negative impact on the efficacy of fURS in the treatment of patients with kidney stone.
Keywords: Flexible ureterorenoscopy (fURS); kidney stone; metabolic syndrome; stone-free rates (SFRs).